en · de · es
faq-desk.peptides5388.com › Guide › Identity And Research Origin — What the Evidence Shows

Identity And Research Origin — What the Evidence Shows

By Editorial Desk · published 2025-08-25 · last reviewed 2025-10-06 · Guide

This is a working overview of hGH fragment, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2025-10-06. Anything still debated is marked as such rather than presented as settled.

Identity and Research Origin

Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.

Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.

Identity and Research Context

AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.

Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.

Aod-9604 at a glance

PropertyValueNotes
Molecular classPeptide fragmentCorresponds to hGH residues 176-191
Common synonymsAOD9604, hGH 176-191Also written as AOD-9604
Typical formLyophilized powderOften supplied in sealed vials
SolubilityWater-solubleDissolves in aqueous buffers
Regulatory statusNot approved as drugBanned in sport; varies by country

Background And Research Context

The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.

In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.

AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.

Related pages on this site

Regulatory and Analytical Context

In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.

Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.

Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.

Identity And Research Background

AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.

AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.

Reference notes

== In fiction == Excretion was traditionally a taboo subject in fiction and was rarely depicted explicitly, although later works have used it for satire, worldbuilding, horror and speculation about technology. The Encyclopedia of Science Fiction notes examples ranging from the reversed social taboos surrounding defecation in Brian Aldiss's The Dark Light Years (1964) to waste-recycling technologies in works such as Frank Herbert's Dune (1965), while spaceflight fiction has sometimes addressed the practical problems of sanitation and waste disposal. Depictions can also serve social or political purposes: Ursula K. Le Guin's "The Ones Who Walk Away from Omelas" (1973) associates excrement with the degradation of the abused child on whom its utopian society depends, while later works have employed toilets and excretion for comedy, horror and speculative depictions of future technology.

The Parliament of South Africa consists of two houses: the National Assembly of South Africa (lower house) and the National Council of Provinces (upper house). Members of both houses are given the title Member of Parliament. The National Assembly is made up of 400 members, who are all elected by the public in general elections using a proportional representation system with closed lists. The National Council of Provinces is composed of 90 delegates with 10 delegates for each of the nine provinces regardless of the population of the province. A provincial delegation consists of six permanent delegates and four special delegates. NCOP delegates are elected by the nine provincial legislatures on the day when they reconvene, usually the same day as the National Assembly. The delegates are sworn in the next day.

=== Adjunctive techniques === Additional procedures may be performed in conjunction with blepharoplasty to support eyelid position and optimize outcomes. These may include canthopexy or canthoplasty to stabilize the lateral eyelid, as well as midface elevation or fat repositioning to improve the transition between the lower eyelid and cheek.

Sources: en.wikipedia.org

Reference notes

== See also == Buried penis Castration anxiety Crotch (in clothing) – a pouch-shaped area built to accommodate a penis and scrotum Micropenis Penile enlargement Penis removal Phallic architecture Phallus – an object or image that resembles a penis Preputioplasty – an operation performed to facilitate retraction of the foreskin Stunt cock – a substitute penis used for filmmaking

Justin McNulty is suspended from the SDLP for leaving the Assembly sitting early to manage Laois GAA at a Gaelic football match in Wexford. Sir Bob Neill, MP for Bromley and Chislehurst, announces he is stand down at the next election to spend more time with his wife, who has suffered a stroke. 4 February – Dafydd Wigley, a former leader of Plaid Cymru, warns that reforms to Wales's political system pose "a very great danger" since it would destroy the relationship between voters and the people they elect. Prime Minister Rishi Sunak arrives in Northern Ireland to visit ministers following the restoration of the Executive. 5 February – Sunak visits Stormont along with Taoiseach Leo Varadkar to mark the restoration of the Northern Ireland Executive. Sunak is criticised by opposition parties after appearing to agree to a £1,000 bet on the Rwanda asylum plan, that the first flight to Rwanda would take off before the election. He subsequently says the challenge, put forward by TalkTV presenter Piers Morgan, took him by surprise, but that it was not a mistake to accept it. Sunak says the government has "not made enough progress" on cutting NHS waiting lists in England, but that industrial action "has had an impact". The UK government sets out its Disability Action Plan, which includes measures to protect people with assistance dogs from being illegally refused entry to businesses. The UK government launches a six-week consultation on plans for Martyn's Law, which would make provisions to better protect the public against potential acts of terrorism.

Crucibles used to contain plutonium need to be able to withstand its strongly reducing properties. Refractory metals such as tantalum and tungsten along with the more stable oxides, borides, carbides, nitrides and silicides can tolerate this. Melting in an electric arc furnace can be used to produce small ingots of the metal without the need for a crucible. Cerium is used as a chemical simulant of plutonium for development of containment, extraction, and other technologies.

==== Cell theory, embryology and germ theory ==== Advances in microscopy also had a profound impact on biological thinking. In the early 19th century, a number of biologists pointed to the central importance of the cell. In 1838 and 1839, Schleiden and Schwann began promoting the ideas that (1) the basic unit of organisms is the cell and (2) that individual cells have all the characteristics of life, though they opposed the idea that (3) all cells come from the division of other cells. Thanks to the work of Robert Remak and Rudolf Virchow, however, by the 1860s most biologists accepted all three tenets of what came to be known as cell theory. Cell theory led biologists to re-envision individual organisms as interdependent assemblages of individual cells. Scientists in the rising field of cytology, armed with increasingly powerful microscopes and new staining methods, soon found that even single cells were far more complex than the homogeneous fluid-filled chambers described by earlier microscopists. Robert Brown had described the nucleus in 1831, and by the end of the 19th century cytologists identified many of the key cell components: chromosomes, centrosomes,s mitochondria, chloroplasts, and other structures made visible through staining. Between 1874 and 1884 Walther Flemming described the discrete stages of mitosis, showing that they were not artifacts of staining but occurred in living cells, and moreover, that chromosomes doubled in number just before the cell divided and a daughter cell was produced.

Sources: en.wikipedia.org

Frequently asked questions

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.

Is AOD-9604 the same as growth hormone?

No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.

How is AOD-9604 regulated?

Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.

What is AOD-9604?

AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.

Network